Prestige Consumer Healthcare Inc. (PBH) presents a deeply negative liquidation recovery posture as of March 31, 2026, driven almost entirely by the composition of its asset base. The company's balance sheet is dominated by goodwill and intangible assets, which together total $2.88 billion (goodwill $581M, intangibles net $2.30B, of which indefinite-lived tradenames account for $2.14B and finite-lived $156M). Under the liquidation lens, all intangibles and goodwill receive a 0% recovery haircut, meaning approximately $2.88 billion of reported book assets contribute zero to liquidation proceeds. This is the primary driver of deeply negative equity recovery. The MFFAIS-reported cash liquidation value of negative $120M and liquid liquidation value of positive $70M confirm the balance sheet is structurally underwater on a pure wind-down basis. The operating liquidation value of $234M reflects some going-concern premium from tangible assets and working capital but does not represent a liquidation floor. On the liability side, the company carries $1.0 billion in long-term debt as of the prior 10-Q period (December 31, 2025): $400M of 5.125% senior notes due 2028 and $600M of 3.750% senior notes due 2031, plus a revolving credit facility. These obligations remain at face value in liquidation and represent the primary senior claim on any recoverable assets. The unfunded defined benefit pension obligation (plan has no assets as of March 31, 2025 or 2026, with projected benefit payments of approximately $2.6M cumulatively over the next five years) is de minimis in the context of total liabilities. Purchase commitments of $15M in aggregate are also face-value claims in a wind-down. Subsequent to the period end, the company entered a definitive agreement to acquire LaCorium Health for approximately $150M, expected to close in Q2 FY2027; this transaction is not reflected on the March 31, 2026 balance sheet but would, if completed, add acquisition-price intangibles and deploy cash or incremental debt — further pressuring the liquidation gap. The FY2026 filing discusses intangible impairment of $12.5M in FY2025 (tradename) in the MD&A and segment footnotes, but this is a prior-period charge. No goodwill impairment is disclosed for FY2026. Filing does not separately tag individual balance sheet line items (cash, AR, inventory, PP&E, total debt, total liabilities, total assets, stockholders equity) in the TAG_CONTEXT provided — all XBRL tags in TAG_CONTEXT are empty — so quantitative recovery arithmetic cannot be sourced from tagged data. All balance sheet figures referenced here derive from narrative and tabular disclosures in the filing body and prior 10-Q. The structural recovery picture is unchanged from the prior period: a brand-acquisition roll-up model where virtually all asset value resides in intangibles that carry zero liquidation recovery.
▼ Community Notes